Tower Research Capital LLC TRC Raises Position in Ventyx Biosciences, Inc. (NASDAQ:VTYX)

Tower Research Capital LLC TRC lifted its stake in Ventyx Biosciences, Inc. (NASDAQ:VTYX) by 1,424.6% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 19,927 shares of the company’s stock after purchasing an additional 18,620 shares during the period. Tower Research Capital LLC TRC’s holdings in Ventyx Biosciences were worth $49,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. SG Americas Securities LLC raised its position in shares of Ventyx Biosciences by 18.3% in the third quarter. SG Americas Securities LLC now owns 23,084 shares of the company’s stock valued at $802,000 after buying an additional 3,568 shares during the last quarter. Bank of New York Mellon Corp boosted its stake in shares of Ventyx Biosciences by 10.4% in the third quarter. Bank of New York Mellon Corp now owns 164,152 shares of the company’s stock valued at $5,701,000 after purchasing an additional 15,450 shares during the period. Brown Advisory Inc. raised its holdings in Ventyx Biosciences by 35.3% in the third quarter. Brown Advisory Inc. now owns 42,481 shares of the company’s stock valued at $1,475,000 after acquiring an additional 11,075 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in Ventyx Biosciences by 36.0% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 7,855 shares of the company’s stock valued at $273,000 after acquiring an additional 2,078 shares in the last quarter. Finally, TD Asset Management Inc raised its holdings in Ventyx Biosciences by 44.9% in the third quarter. TD Asset Management Inc now owns 155,408 shares of the company’s stock valued at $5,397,000 after acquiring an additional 48,121 shares in the last quarter. Institutional investors and hedge funds own 97.88% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts recently issued reports on VTYX shares. Wells Fargo & Company raised shares of Ventyx Biosciences from an “equal weight” rating to an “overweight” rating and upped their price target for the company from $7.00 to $16.00 in a report on Tuesday, March 12th. Oppenheimer raised shares of Ventyx Biosciences from a “market perform” rating to an “outperform” rating and set a $12.00 price target on the stock in a report on Tuesday, March 12th. Canaccord Genuity Group cut their price target on shares of Ventyx Biosciences from $16.00 to $15.00 and set a “buy” rating on the stock in a report on Wednesday, March 13th. Finally, Lifesci Capital raised shares of Ventyx Biosciences from a “market perform” rating to an “outperform” rating in a report on Wednesday, February 28th. Four analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $21.75.

Ventyx Biosciences Price Performance

VTYX traded down $0.09 during midday trading on Tuesday, hitting $3.74. 2,685,945 shares of the company’s stock traded hands, compared to its average volume of 3,555,057. The company has a market cap of $263.67 million, a PE ratio of -1.13 and a beta of 0.27. The stock’s fifty day simple moving average is $6.14 and its 200-day simple moving average is $5.18. Ventyx Biosciences, Inc. has a one year low of $1.87 and a one year high of $40.58.

Ventyx Biosciences (NASDAQ:VTYX) last announced its quarterly earnings results on Tuesday, February 27th. The company reported ($0.79) EPS for the quarter, beating the consensus estimate of ($0.87) by $0.08. During the same period last year, the company posted ($0.62) EPS. On average, research analysts expect that Ventyx Biosciences, Inc. will post -2.55 EPS for the current year.

About Ventyx Biosciences

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease.